Clinical trials: Initial
Advanced Solid Tumor
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid…
- Trial name
- NCT07414836
- Testing
- BG-C0979, Tislelizumab
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 84 people
- Sponsor
- BeOne Medicines
Biliary Tract Cancer (BTC)
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem])
- Trial name
- TELE-ABC (NCT03790111)
- Testing
- telotristat ethyl
- Where
- 14 sites in United States
- Volunteers
- 53 people
- Sponsor
- TerSera Therapeutics LLC
Scabies
Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)
The ETSKABI study is a prospective, open-label, multicenter, initially single-armed and in case of treatment failure subsequently three-armed randomized clinical trial.
- Trial name
- ETSKABI (NCT04814511)
- Testing
- InfectoScab 5 % Creme, Permethrin 10 % Creme, Driponin 3 mg Tabletten
- Where
- 8 sites in Germany
- Volunteers
- 183 people
- Sponsor
- Infectopharm Arzneimittel GmbH
Hepatocellular Carcinoma
Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment
Researchers already did trials that showed Sorafenib and Regorafenib worked for patients with hepatocellular carcinoma (most common liver tumor type).
- Trial name
- SORAGO-HCC (NCT03644511)
- Testing
- Regorafenib (Stivarga, BAY73-4506), Sorafenib (Nexavar, BAY43-9006)
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- Bayer
Acute GVH Disease
MTX and Steroid as First-line Therapy for aGVHD
The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid as first-line therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation…
- Trial name
- NCT04960644
- Testing
- MTX, Corticosteroid
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Peking University People's Hospital
CAR-T Cell Therapy, High-risk Large B-cell Lymphoma (LBCL)
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
The goal of this is Single-Arm, Multicenter, Open-Label Clinical Study is to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection(Axi-cel) as First-Line Therapy of High-Risk Large B-Cell Lymphoma.
- Trial name
- NCT06935136
- Testing
- Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
HIV Infections
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens.
- Trial name
- PEARLS (NCT00084136)
- Testing
- Atazanavir, Didanosine (enteric-coated), Efavirenz
- Where
- 42 sites in United States, Brazil and 7 more
- Volunteers
- 1,571 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
FIGO Stage IIC-IV Ovarian Carcinoma, Fallopian Tube Carcinoma
Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer
This phase I trial studies the side effects and best dose of heated carboplatin given into the abdomen at the time of surgery in treating patients with stage II-IV ovarian, fallopian tube, or peritoneal cancer.
- Conditions
- FIGO Stage IIC-IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- NCT02199171
- Testing
- carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Irvine
Pompe Disease
First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221
This is an international, multi-center, open-label study designed to evaluate if the co-administration of investigational new drugs ATB200 and AT2221 is safe in adults with Pompe disease.
- Trial name
- NCT02675465
- Testing
- ATB200, AT2221
- Where
- 19 sites in United States, Australia and 4 more
- Volunteers
- 29 people
- Sponsor
- Amicus Therapeutics
Unresectable Pancreatic Cancer
Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
Background: Monotherapy with S-1, oral fluoropyrimidine, shows non-inferiority to gemcitabine in overall survival (OS) with good tolerability for advanced pancreatic cancer in Asian patients.
- Trial name
- NCT02945267
- Testing
- Nimotuzumab plus S1
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Ovulation Induction, Polycystic Ovary Syndrome
Myo-inositol Versus Clomiphene Citrate in PCOS
Specific aim: To compare inositol and the golden standard first line treatment of ovulation induction, namely clomiphene citrate.
- Conditions
- Ovulation Induction, Polycystic Ovary Syndrome, Clomiphene, Inositol
- Trial name
- NCT04306692
- Testing
- Myo-inositol, Clomiphene Citrate
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- University Hospital, Ghent
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
This phase II trial is studying how well triapine works as first-line or second-line therapy in treating patients with locally advanced or metastatic adenocarcinoma (cancer) of the pancreas.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00085371
- Testing
- triapine
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Cognitive/Functional Effects, Colorectal Cancer
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
This randomized phase III trial studies how well combination chemotherapy plus bevacizumab with or without oxaliplatin works in treating older patients with colorectal cancer that has spread to other places in the body.
- Conditions
- Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT01279681
- Testing
- bevacizumab, capecitabine, fluorouracil
- Volunteers
- 32 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Kidney Failure, Chronic
Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis
To show non-inferiority in the incidence rates of elevated calcium-phosphorus product between two treatment groups: 1) a group having an initial dose based on baseline PTH (baseline iPTH/80) and 2) a group having a starting dose…
- Trial name
- NCT00091481
- Testing
- Zemplar
- Where
- 19 sites in Greece
- Volunteers
- 201 people
- Sponsor
- Abbott
Stroke
FIRST-Oslo Long-term Follow-up
The study aims to describe the functional level of the patients who received high intensity gait training during inpatient stroke rehabilitation at discharge, three, six and twelve months after stroke.
- Trial name
- NCT04870619
- Testing
- High Intensity Gait Training
- Where
- 2 sites in Norway
- Volunteers
- 69 people
- Sponsor
- Oslo University Hospital
Ovarian Cancer
A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This is a Prospective,Single-Center, Single-Arm, Phase 2 study to evaluate the efficacy and safety of Fluzoparib Combined With QL1101, as maintenance treatment, in patients with Advanced FIGO Stage III or IV High Grade Serous or…
- Trial name
- NCT05585281
- Testing
- Fluzoparib, QL1101
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Yongpeng Wang
Hematologic Diseases, Anaemia, Sickle Cell
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
This will be a first time in human (FTIH) study in sickle cell diseases (SCD) participants. The FTIH study is planned to evaluate the safety, tolerability, and pharmacokinetics of GSK4172239D.
- Trial name
- NCT05660265
- Testing
- GSK4172239D
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Malocclusion, Angle Class III
Evaluation of Surgical Outcomes of Patients Treated With the Surgery First Approach and Aligners
The purpose of this prospective study is to compare treatment outcomes and the quality of life of skeletal Class III patients treated with conventional fixed appliances and aligners undergoing Surgery-first approach.
- Trial name
- NCT05822271
- Testing
- Orthognathic Surgery
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rio de Janeiro State University
Hepato Cellular Carcinoma (HCC)
First Line Hepato Cellular Carcinoma (HCC)
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
- Trial name
- BRISK FL (NCT00858871)
- Testing
- Brivanib, Sorafenib
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 1,714 people
- Sponsor
- Bristol-Myers Squibb
Premature Ventricular Contractions, Ventricular Tachycardia
CHU Dual-Energy Ablation in Ventricular Arrhythmia
The objective of this study is to evaluate the safety of the dual-energy ablation catheter manufactured by Shanghai MicroPort EP Medical Technology Co., Ltd. in the treatment of tachyarrhythmias.
- Trial name
- CHU-VA (NCT07503769)
- Testing
- ablation
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai MicroPort EP MedTech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.